サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1683382

血管内皮増殖因子受容体（VEGFR）阻害剤の世界市場：2025年～2033年

Global Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitors Market - 2025-2033

出版日
ページ情報
英文 176 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
血管内皮増殖因子受容体（VEGFR）阻害剤の世界市場：2025年～2033年
出版日: 2025年03月20日
発行: DataM Intelligence
ページ情報: 英文 176 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の血管内皮増殖因子受容体（VEGFR）阻害剤の市場規模は、2024年に141億2,000万米ドルに達し、2033年には223億4,000万米ドルに達するとみられ、2025年から2033年の予測期間中に5.9％のCAGRで拡大すると予測されています。

血管内皮増殖因子（VEGF）および血管内皮増殖因子受容体（VEGFR）阻害剤は、VEGFおよびVEGFRの活性を阻害する治療薬であり、血管新生（既存の血管から新しい血管が形成されること）において重要な役割を果たしています。VEGFとVEGFRのシグナル伝達は、がんの進行、変性眼疾患、炎症性疾患など、様々な生理的・病理的プロセスにとって重要です。

がんでは、異常な血管新生が腫瘍の成長と転移を促進するため、VEGF/VEGFR阻害剤はこれらの経路を遮断する上で重要です。これらの阻害剤には、VEGFそのものを標的とするモノクローナル抗体（例：ベバシズマブ）とVEGFRを標的とするチロシンキナーゼ阻害剤（TKI）（例：パゾパニブ）があります。これらの薬剤は、腎細胞がん、結腸直腸がん、肝細胞がんなどの様々ながんの治療に広く使用されています。

チロシンキナーゼ阻害剤（TKI）は最も一般的なVEGFR阻害剤で、血管新生と腫瘍増殖に必要な細胞内シグナル伝達を遮断します。一般的な例としては、パゾパニブ、スニチニブ、カボザンチニブなどがあります。モノクローナル抗体（mAbs）阻害薬は、VEGF分子またはその受容体に直接結合し、VEGFが血管新生を引き起こすのを阻止します。ベバシズマブのような薬剤はこのカテゴリーに属します。

血管内皮増殖因子受容体（VEGFR）阻害剤市場は、がんの罹患率と有病率の上昇が世界市場の成長を大きく牽引しており、市場予測期間中も牽引していくと予想されます。がんは世界的に主要な死因の一つであり、高齢化、ライフスタイルの変化、環境の影響などの要因により、その罹患率は上昇すると予想されています。

例えば、2022年のGlobocanのデータによると、男性のがん罹患率は1,030万人、女性は970万人でした。2025年には、がん罹患率は男性で1,250万人、女性で1,160万人に達すると予測されています。世界のがん罹患率の増加が続く中、VEGFR阻害剤を含む効果的な治療オプションに対する需要が急増しています。

さらに、業界の主要企業は、この市場成長の原動力となる製品の上市や承認を発表しています。例えば、2023年11月、HUTCHMEDは、Takedaが化学療法と抗VEGF治療を既に受けた成人の転移性大腸がん（mCRC）の治療薬としてFRUZAQLA（fruquintinib）の米国FDA承認を取得したと発表しました。今回の承認は、フルキンチニブが前治療歴のある転移性結腸・直腸がん患者の全生存期間（OS）と無増悪生存期間（PFS）を有意に改善することを示した第3相試験FRESCO-2のデータに基づいています。これらすべての要因が、世界の血管内皮増殖因子受容体（VEGFR）阻害剤市場に需要をもたらしています。

治療費の高さは、血管内皮増殖因子受容体（VEGFR）阻害剤の世界市場の成長を阻害します。チロシンキナーゼ阻害剤（TKI）やモノクローナル抗体を含むVEGFR阻害剤は、その複雑な開発プロセス、高い製造コスト、治療の特殊性から、最も高額ながん治療薬のひとつです。この経済的負担は、特に腎細胞がん、大腸がん、肝細胞がんのように継続的な管理が必要ながんでは、治療期間が長いために悪化します。

高コストの主な要因は、これらの薬剤を市場に投入するために必要な研究開発（R&D）投資です。例えば、ベバシズマブ単剤療法のような薬剤は、11年間の個々の治療費が14,772ドルで、社会的リターンは357,680ドルであり、投資利益率（ROI）は2,421％という驚異的な結果となっています。これに対し、ラニビズマブ治療は106,582ドルで、265,870ドルの社会的リターンをもたらし（ROI249％）、アフリベルセプト治療は61,811ドルで、310,611ドルの社会的リターンをもたらしました（ROI503％）。2018年のNVAMD治療コホートでは、11年間の社会的利益の合計は285億米ドルと推定され、242億米ドル（約85％）がベバシズマブ、7億米ドル（2.5％）がラニビズマブ、36億米ドル（12.6％）がアフリベルセプトに起因します。したがって、上記の要因が世界の血管内皮増殖因子受容体（VEGFR）阻害剤市場の潜在的成長を制限している可能性があります。

当レポートでは、世界の血管内皮増殖因子受容体（VEGFR）阻害剤市場について調査し、市場の概要とともに、タイプ別、薬剤タイプ別、用途別、投与経路別、地域別動向、競合情勢、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 調査手法と範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
    • 抑制要因
    • 機会
    • 影響分析

第5章 戦略的洞察と業界の展望

  • 市場のリーダーと先駆者
  • CXOの視点
  • 最新の開発とブレークスルー
  • ケーススタディ/進行中の調査
  • 規制と償還の情勢
  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 特許分析
  • SWOT分析
  • アンメットニーズとギャップ
  • 市場参入と拡大のための推奨戦略
  • シナリオ分析ベストケース、ベースケース、ワーストケースの予測
  • 価格分析と価格動向
  • キーオピニオンリーダー

第6章 タイプ別

  • VEGF-A
  • VEGF-B
  • VEGF-C
  • VEGF-D

第7章 薬剤タイプ別

  • チロシンキナーゼ阻害剤（TKI）
  • モノクローナル抗体

第8章 用途別

  • 進行性腎細胞がん
  • 進行性大腸がん
  • 転移性大腸がん（mCRC）
  • 進行性非扁平上皮非小細胞肺がん（NSCLC）
  • 再発性神経膠芽腫（rGBM）
  • 卵巣がん（OC）
  • 肝細胞がん
  • 甲状腺がん
  • 非小細胞肺がん（NSCLC）
  • 滲出型加齢黄斑変性症（AMD）
  • 糖尿病黄斑浮腫（DME）
  • 網膜静脈閉塞症（RVO）
  • その他

第9章 投与経路別

  • 経口
  • 静脈内
  • 硝子体内

第10章 地域別

  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他
  • ラテンアメリカ
    • メキシコ
    • ブラジル
    • アルゼンチン
    • その他
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他
  • 中東・アフリカ

第11章 競合情勢

第12章 企業プロファイル

  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Amgen Inc.
  • Pfizer Inc.
  • Biocon
  • Exelixis, Inc.
  • Bayer AG
  • Eisai Co., Ltd.
  • Takeda Pharmaceuticals USA, Inc.
  • Sanofi（Regeneron Pharmaceuticals, Inc.）
  • AVEO Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • Genentech USA, Inc.

第13章 付録

目次
Product Code: PH9322

The global vascular endothelial growth factor receptor (VEGFR) inhibitors market reached US$ 14.12 billion in 2024 and is expected to reach US$ 22.34 billion by 2033, growing at a CAGR of 5.9 % during the forecast period of 2025-2033.

Vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) inhibitors are therapeutic agents that block the activity of VEGF and VEGFR, which play a key role in angiogenesis, the formation of new blood vessels from existing ones. VEGF and VEGFR signaling is critical for various physiological and pathological processes, including cancer progression, degenerative eye conditions, and inflammatory diseases.

In cancer, abnormal angiogenesis facilitates tumor growth and metastasis, making VEGF/VEGFR inhibitors important in blocking these pathways. These inhibitors include monoclonal antibodies that target VEGF itself (e.g., bevacizumab) and tyrosine kinase inhibitors (TKIs) that target VEGFR (e.g., pazopanib). These drugs are widely used to treat different cancers, such as renal cell carcinoma, colorectal cancer, and hepatocellular carcinoma, among others.

Tyrosine kinase inhibitors (TKIs) are the most common VEGFR inhibitors, which block the intracellular signaling required for angiogenesis and tumor growth. Common examples include pazopanib, sunitinib, and cabozantinib. Monoclonal antibody (mAbs) inhibitors directly bind to the VEGF molecule or its receptor, preventing it from triggering angiogenesis. Drugs like bevacizumab fall into this category.

Market Dynamics: Drivers & Restraints

Rising Incidence and Prevalence of Cancer

The rising incidence and prevalence of cancer are significantly driving the growth of the global vascular endothelial growth factor receptor (VEGFR) inhibitors market and are expected to drive it throughout the market forecast period. Cancer is one of the leading causes of death worldwide, and its incidence is expected to rise due to factors such as aging populations, lifestyle changes, and environmental influences.

For instance, according to the globocon data in 2022, the cancer incidence for males was 10.3 million, while for females, it was 9.7 million. By 2025, the cancer incidence is projected to reach 12.5 million for males and 11.6 million for females. As the global cancer burden continues to increase, the demand for effective treatment options, including VEGFR inhibitors, has surged.

Additionally, key players in the industry have announced product launches and approvals that would drive this market growth. For instance, in November 2023, HUTCHMED announced that Takeda has received U.S. FDA approval for FRUZAQLA (fruquintinib) to treat metastatic colorectal cancer (mCRC) in adults who have already undergone prior chemotherapy and anti-VEGF treatment. The approval is based on data from the Phase 3 FRESCO-2 trial, which demonstrated that fruquintinib significantly improves both overall survival (OS) and progression-free survival (PFS) in patients with previously treated mCRC. All these factors demand the global vascular endothelial growth factor receptor (VEGFR) inhibitors market.

High Cost of Treatment

The high cost of treatment will hinder the growth of the global vascular endothelial growth factor receptor (VEGFR) inhibitors market. VEGFR inhibitors, including tyrosine kinase inhibitors (TKIs) and monoclonal antibodies, are among the most expensive cancer therapies due to their complex development processes, high manufacturing costs, and the specialized nature of the treatments. This financial burden is exacerbated by the long duration of treatment, especially in cancers that require ongoing management, such as renal cell carcinoma, colorectal cancer, and hepatocellular carcinoma.

A key factor contributing to the high costs is the research and development (R&D) investment needed to bring these drugs to market. For instance, drugs like Bevacizumab monotherapy had an individual treatment cost of $14,772 over 11 years, with a societal return of $357,680, resulting in an impressive 2,421% return on investment (ROI). In comparison, ranibizumab therapy cost $106,582, yielding a societal return of $265,870 (249% ROI), while aflibercept treatment cost $61,811 and generated $310,611 in societal returns (503% ROI). For the 2018 NVAMD treatment cohort, the total 11-year societal gain was estimated at $28.5 billion, with $24.2 billion (about 85%) attributed to bevacizumab, $0.7 billion (2.5%) to ranibizumab, and $3.6 billion (12.6%) to aflibercept. Thus, the above factors could be limiting the global vascular endothelial growth factor receptor (VEGFR) inhibitors market's potential growth.

Segment Analysis

The global vascular endothelial growth factor receptor (VEGFR) inhibitors market is segmented based on type, drug type, application, route of administration, and region.

Drug Type:

The tyrosine kinase inhibitor (TKI) segment in the drug type is expected to dominate the global vascular endothelial growth factor receptor (VEGFR) inhibitors market

The tyrosine kinase inhibitor (TKI) segment plays a crucial role in the global vascular endothelial growth factor receptor (VEGFR) inhibitors market, largely driven by the increasing demand for targeted cancer therapies. TKIs block VEGFR signaling, which is essential for angiogenesis, the process of forming new blood vessels that support tumor growth and metastasis. By targeting this pathway, TKIs help limit the blood supply to tumors, inhibiting their growth and spread. This has made them particularly effective in treating various cancers, such as renal cell carcinoma, colorectal cancer, and hepatocellular carcinoma.

Notable TKIs in the VEGFR inhibitor market include pazopanib, sunitinib, cabozantinib, lenvatinib, and regorafenib. These drugs are designed to specifically block VEGFR and interfere with the angiogenesis process, thereby preventing tumors from forming the blood vessels they need to grow. The TKI segment has been strengthened by strong clinical trial data, showing that these inhibitors are effective both as monotherapies and in combination with other cancer treatments. This has expanded their use across multiple cancer types, boosting their market demand.

Additionally, key players in the industry's product launches and approvals would drive this segment growth in the market. For instance, in December 2023, the U.S. Food and Drug Administration (FDA) approved belzutifan (Welireg) for the treatment of advanced renal cell carcinoma (RCC) in patients who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI). These factors have solidified the segment's position in the global vascular endothelial growth factor receptor (VEGFR) inhibitors market.

Geographical Analysis

North America is expected to hold a significant position in the global vascular endothelial growth factor receptor (VEGFR) inhibitors market share

North America holds a substantial position in the global vascular endothelial growth factor receptor (VEGFR) inhibitors market and is expected to hold most of the market share. The increasing prevalence of diseases such as cancer, which require targeted treatments to inhibit angiogenesis, is driving the growing demand for VEGFR inhibitors. These therapies, which disrupt the formation of blood vessels that support tumor growth, are becoming essential in managing various cancers, thus leading to a significant rise in their market adoption.

According to the National Institutes of Health (NIH) data in May 2024, cancer has a significant impact on society both in the United States and globally. Cancer statistics offer insight into the scope of the disease and reflect its burden on society. In 2024, it is estimated that 2,001,140 new cases of cancer will be diagnosed in the United States, and 611,720 people will succumb to the disease. The escalating incidence of cancer underscores the urgent need for VEGFR inhibitor solutions.

Both the U.S. and Canada have significantly increased their investments in healthcare research and development (R&D), which has played a pivotal role in advancing VEGFR-targeted therapies. This enhanced financial support is expected to continue driving market growth in the coming years.Furthermore, the adoption of cutting-edge medical technologies, including advanced diagnostic tools, is accelerating the use of VEGFR inhibitors. As healthcare providers increasingly incorporate these technologies into personalized treatment plans, the demand for these therapies is growing, contributing to the overall expansion of the market.

In this region, a major number of key players are present, with well-advanced healthcare infrastructure, government initiatives, and product approvals that would drive this market growth. For instance, in October 2024, Elevar Therapeutics announced the acceptance of its New Drug Application (NDA) for rivoceranib, in combination with camrelizumab, by the U.S. FDA. This combination therapy is being proposed as a first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC), a form of liver cancer. Thus, the above factors are consolidating the region's position as a dominant force in the global vascular endothelial growth factor receptor (VEGFR) inhibitors market.

Competitive Landscape

The major global players in the vascular endothelial growth factor receptor (VEGFR) inhibitors market include Novartis AG, F. Hoffmann-La Roche Ltd, Amgen Inc., Pfizer Inc., Biocon, Exelixis, Inc., Bayer AG, Eisai Co., Ltd., Takeda Pharmaceuticals U.S.A., Inc., Sanofi (Regeneron Pharmaceuticals, Inc.), AVEO Pharmaceuticals, Inc., Eli Lilly and Company, and Genentech USA, Inc. among others.

Key Developments

  • In September 2024, Takeda received approval in Japan for FRUZAQLA (fruquintinib) to treat unresectable advanced or recurrent colorectal cancer (CRC). This approval was granted by the Japanese Ministry of Health, Labour and Welfare (MHLW) and is based on results from the FRESCO-2 global Phase 3 trial.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials and product pipelines and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzed product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global vascular endothelial growth factor receptor (VEGFR) inhibitors market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Drug Type
  • 3.3. Snippet by Application
  • 3.4. Snippet by Route of Administration
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Incidence and Prevalence of Cancer
      • 4.1.1.2. Advancements in Drug Development & Biosimilars
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost of Treatment
      • 4.1.2.2. Adverse Side Effects Associated with the Treatment
    • 4.1.3. Opportunity
      • 4.1.3.1. Technological Advancements and Combination Therapies
    • 4.1.4. Impact Analysis

5. Strategic Insights and Industry Outlook

  • 5.1. Market Leaders and Pioneers
    • 5.1.1. Emerging Pioneers and Prominent Players
    • 5.1.2. Established leaders with largest selling Brand
    • 5.1.3. Market leaders with established Product
  • 5.2. CXO Perspectives
  • 5.3. Latest Developments and Breakthroughs
  • 5.4. Case Studies/Ongoing Research
  • 5.5. Regulatory and Reimbursement Landscape
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa
  • 5.6. Porter's Five Forces Analysis
  • 5.7. Supply Chain Analysis
  • 5.8. Patent Analysis
  • 5.9. SWOT Analysis
  • 5.10. Unmet Needs and Gaps
  • 5.11. Recommended Strategies for Market Entry and Expansion
  • 5.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 5.13. Pricing Analysis and Price Dynamics
  • 5.14. Key Opinion Leaders

6. By Type

  • 6.1. Introduction
    • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Type
    • 6.1.2. Market Attractiveness Index By Type
  • 6.2. VEGF-A*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. VEGF-B
  • 6.4. VEGF-C
  • 6.5. VEGF-D

7. By Drug Type

  • 7.1. Introduction
    • 7.1.1. Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 7.1.2. Market Attractiveness Index By Drug Type
  • 7.2. Tyrosine Kinase Inhibitor (TKI)*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.3. Pazopanib
    • 7.2.4. Sunitinib Malate
    • 7.2.5. Cabozantinib
    • 7.2.6. Sorafenib
    • 7.2.7. Lenvatinib
    • 7.2.8. Regorafenib
    • 7.2.9. Axitinib
    • 7.2.10. Ponatinib
    • 7.2.11. Tivozanib
    • 7.2.12. Others
  • 7.3. Monoclonal Antibody
    • 7.3.1. Bevacizumab
    • 7.3.2. Brolucizumab
    • 7.3.3. Ramucirumab
    • 7.3.4. Ranibizumab
    • 7.3.5. Faricimab
    • 7.3.6. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index By Application
  • 8.2. Advanced Renal Cell Carcinoma*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Advanced Colorectal Cancer
  • 8.4. Metastatic Colorectal Cancer (mCRC)
  • 8.5. Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
  • 8.6. Recurrent Glioblastoma (rGBM)
  • 8.7. Ovarian Cancer (OC)
  • 8.8. Hepatocellular Carcinoma
  • 8.9. Thyroid cancer
  • 8.10. Non-Small Cell Lung Cancer (NSCLC)
  • 8.11. Wet Age-Related Macular Degeneration (AMD)
  • 8.12. Diabetic Macular Edema (DME)
  • 8.13. Retinal Vein Occlusion (RVO)
  • 8.14. Others

9. By Route of Administration

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.1.2. Market Attractiveness Index By Route of Administration
  • 9.2. Oral*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Intravenous
  • 9.4. Intravitreal

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.7.1. U.S.
      • 10.2.7.2. Canada
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.7.1. Germany
      • 10.3.7.2. U.K.
      • 10.3.7.3. France
      • 10.3.7.4. Spain
      • 10.3.7.5. Italy
      • 10.3.7.6. Rest of Europe
  • 10.4. Latin America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.7.1. Mexico
      • 10.4.7.2. Brazil
      • 10.4.7.3. Argentina
      • 10.4.7.4. Rest of Latin America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. South Korea
      • 10.5.7.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Novartis AG*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio
      • 12.1.2.1. Product Description
      • 12.1.2.2. Product Key Performance Indicators (KPIs)
      • 12.1.2.3. Historic and Forecasted Product Sales
      • 12.1.2.4. Product Sales Volume
    • 12.1.3. Financial Overview
      • 12.1.3.1. Company Revenue's
      • 12.1.3.2. Geographical Revenue Shares
      • 12.1.3.3. Revenue Forecasts
    • 12.1.4. Key Developments
      • 12.1.4.1. Mergers & Acquisitions
      • 12.1.4.2. Key Product Development Activities
      • 12.1.4.3. Regulatory Approvals, etc.
    • 12.1.5. SWOT Analysis
  • 12.2. F. Hoffmann-La Roche Ltd
  • 12.3. Amgen Inc.
  • 12.4. Pfizer Inc.
  • 12.5. Biocon
  • 12.6. Exelixis, Inc.
  • 12.7. Bayer AG
  • 12.8. Eisai Co., Ltd.
  • 12.9. Takeda Pharmaceuticals U.S.A., Inc.
  • 12.10. Sanofi (Regeneron Pharmaceuticals, Inc.)
  • 12.11. AVEO Pharmaceuticals, Inc.
  • 12.12. Eli Lilly and Company
  • 12.13. Genentech USA, Inc.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us